Frequent Disruption of Chromodomain Helicase DNA-Binding Protein 8 (CHD8) and Functionally Associated Chromatin Regulators in Prostate Cancer

Neoplasia (United States)

Volumn 16, Issue 12, 2014, Pages 1018-1027

  Damaschke, Nathan A ^a   Yang, Bing ^a   Blute, Michael L ^a   Lin, Chee Paul ^a   Huang, Wei ^a   Jarrard, David F ^a,b,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMATIN HELICASE DNA BINDING PROTEIN 8; DECITABINE; PROTEIN; TRANSCRIPTION FACTOR CTCF; UNCLASSIFIED DRUG; CCCTC-BINDING FACTOR; CHD8 PROTEIN, HUMAN; CHROMATIN; CTCFL PROTEIN, HUMAN; DNA BINDING PROTEIN; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR;

AMINO TERMINAL SEQUENCE; ARTICLE; BIOCHEMICAL RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CELL HETEROGENEITY; CELL NUCLEUS; CHROMATIN; CHROMATIN REGULATION; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL OUTCOME; CONTROLLED STUDY; CYTOPLASM; DNA METHYLATION; EPIGENETICS; GENE DELETION; GENE EXPRESSION; GENETIC REGULATION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGING SYSTEM; MALE; METASTASIS; PATHOLOGY; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PYROSEQUENCING; QUANTITATIVE ANALYSIS; RECURRENCE FREE SURVIVAL; SURGICAL MARGIN; TRANSCRIPTION INITIATION SITE; TREATMENT FAILURE; CARCINOMA IN SITU; CPG ISLAND; GENE EXPRESSION REGULATION; GENETICS; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL CULTURE;

CARCINOMA IN SITU; CHROMATIN; CPG ISLANDS; DNA METHYLATION; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 85003220372     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2014.10.003     Document Type: Article

References (33)

1. Damaschke, N.A., Yang, B., Bhusari, S., Svaren, J.P., Jarrard, D.F., Epigenetic susceptibility factors for prostate cancer with aging Prostate 73 (2013), 1721–1730.
2. Varambally, S., Dhanasekaran, S.M., Zhou, M., Barrette, T.R., Kumar-Sinha, C., Sanda, M.G., Ghosh, D., Pienta, K.J., Sewalt, R.G., Otte, A.P., et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419 (2002), 624–629.
3. Ishihara, K., Oshimura, M., Nakao, M., CTCF-dependent chromatin insulator is linked to epigenetic remodeling. Mol Cell 23 (2006), 733–742.
4. Loukinov, D.I., Pugacheva, E., Vatolin, S., Pack, S.D., Moon, H., Chernukhin, I., Mannan, P., Larsson, E., Kanduri, C., Vostrov, A.A., et al. BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc Natl Acad Sci U S A 99 (2002), 6806–6811.
5. Vatolin, S., Abdullaev, Z., Pack, S.D., Flanagan, P.T., Custer, M., Loukinov, D.I., Pugacheva, E., Hong, J.A., Morse, H., Schrump, D.S., et al. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res 65 (2005), 7751–7762.
6. Merkenschlager, M., Odom, D.T., CTCF and cohesin: linking gene regulatory elements with their targets. Cell 152 (2013), 1285–1297.
7. Fiorentino, F.P., Giordano, A., The tumor suppressor role of CTCF. J Cell Physiol 227 (2012), 479–492.
8. Kurukuti, S., Tiwari, V.K., Tavoosidana, G., Pugacheva, E., Murrell, A., Zhao, Z., Lobanenkov, V., Reik, W., Ohlsson, R., CTCF binding at the H19 imprinting control region mediates maternally inherited higher-order chromatin conformation to restrict enhancer access to Igf2. Proc Natl Acad Sci U S A 103 (2006), 10684–10689.
9. Hore, T.A., Deakin, J.E., Marshall Graves, J.A., The evolution of epigenetic regulators CTCF and BORIS/CTCFL in amniotes. PLoS Genet, 4, 2008, e1000169.
10. Klenova, E.M., Morse, H.C., Ohlsson, R., Lobanenkov, V.V., The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. Semin Cancer Biol 12 (2002), 399–414.
11. Pugacheva, EM, Suzuki, T, Pack, SD, The structural complexity of the human BORIS gene in gametogenesis and cancer. PLoS One, 5, 2010, e13872.
12. Cheema, Z., Hari-Gupta, Y., Kita, G.X., Farrar, D., Seddon, I., Corr, J., Klenova, E., Expression of the cancer-testis antigen BORIS correlates with prostate cancer. Prostate 74 (2014), 164–176.
13. Marfella, C.G., Imbalzano, A.N., The Chd family of chromatin remodelers. Mutat Res 618 (2007), 30–40.
14. Kim, M.S., Chung, N.G., Kang, M.R., Yoo, N.J., Lee, S.H., Genetic and expressional alterations of CHD genes in gastric and colorectal cancers. Histopathology 58 (2011), 660–668.
15. Nishiyama, M., Oshikawa, K., Tsukada, Y., Nakagawa, T., Iemura, S., Natsume, T., Fan, Y., Kikuchi, A., Skoultchi, A.I., Nakayama, K.I., CHD8 suppresses p53-mediated apoptosis through histone H1 recruitment during early embryogenesis. Nat Cell Biol 11 (2009), 172–182.
16. Nishiyama, M., Skoultchi, A.I., Nakayama, K.I., Histone H1 recruitment by CHD8 is essential for suppression of the Wnt-β-catenin signaling pathway. Mol Cell Biol 32 (2012), 501–512.
17. Yates, J.A., Menon, T., Thompson, B.A., Bochar, D.A., Regulation of HOXA2 gene expression by the ATP-dependent chromatin remodeling enzyme CHD8. FEBS Lett 584 (2010), 689–693.
18. Menon, T., Yates, J.A., Bochar, D.A., Regulation of androgen-responsive transcription by the chromatin remodeling factor CHD8. Mol Endocrinol 24 (2010), 1165–1174.
19. Subtil-Rodríguez, A., Vázquez-Chávez, E., Ceballos-Chávez, M., Rodríguez-Paredes, M., Martín-Subero, J.I., Esteller, M., Reyes, J.C., The chromatin remodeller CHD8 is required for E2F-dependent transcription activation of S-phase genes. Nucleic Acids Res 42 (2014), 2185–2196.
20. Huang, W., Hennrick, K., Drew, S., A colorful future of quantitative pathology: validation of Vectra technology using chromogenic multiplexed immunohistochemistry and prostate tissue microarrays. Hum Pathol 44 (2013), 29–38.
21. Desotelle, J., Truong, M., Ewald, J., Weeratunga, P., Yang, B., Huang, W., Jarrard, D., CpG island hypermethylation frequently silences FILIP1L isoform 2 expression in prostate cancer. J Urol 189 (2013), 329–335.
22. Kobayashi, Y., Absher, D.M., Gulzar, Z.G., Young, S.R., McKenney, J.K., Peehl, D.M., Brooks, J.D., Myers, R.M., Sherlock, G., DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res 21 (2011), 1017–1027.
23. Rodríguez-Paredes, M., Ceballos-Chávez, M., Esteller, M., García-Domínguez, M., Reyes, J.C., The chromatin remodeling factor CHD8 interacts with elongating RNA polymerase II and controls expression of the cyclin E2 gene. Nucleic Acids Res 37 (2009), 2449–2460.
24. Peet, R.K., The Measurement of Species Diversity. Annual Review of Ecology and Systematics 5 (1974), 285–307.
25. Faratian, D., Christiansen, J., Gustavson, M., Jones, C., Scott, C., Um, I., Harrison, D.J., Heterogeneity mapping of protein expression in tumors using quantitative immunofluorescence. J Vis Exp, 2011, e3334.
26. Phillips, J.E., Corces, V.G., CTCF: master weaver of the genome. Cell 137 (2009), 1194–1211.
27. Hong, J.A., Kang, Y., Abdullaev, Z., Flanagan, P.T., Pack, S.D., Fischette, M.R., Adnani, M.T., Loukinov, D.I., Vatolin, S., Risinger, J.I., et al. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res 65 (2005), 7763–7774.
28. Woloszynska-Read, A., Zhang, W., Yu, J., Link, P.A., Mhawech-Fauceglia, P., Collamat, G., Akers, S.N., Ostler, K.R., Godley, L.A., Odunsi, K., et al. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage. Clin Cancer Res 17 (2011), 2170–2180.
29. Bell, A.C., West, A.G., Felsenfeld, G., The protein CTCF is required for the enhancer blocking activity of vertebrate insulators. Cell 98 (1999), 387–396.
30. Klenova, E.M., Nicolas, R.H., Paterson, H.F., Carne, A.F., Heath, C.M., Goodwin, G.H., Neiman, P.E., Lobanenkov, V.V., CTCF, a conserved nuclear factor required for optimal transcriptional activity of the chicken c-myc gene, is an 11-Zn-finger protein differentially expressed in multiple forms. Mol Cell Biol 13 (1993), 7612–7624.
31. Robbins, C.M., Tembe, W.A., Baker, A., Sinari, S., Moses, T.Y., Beckstrom-Sternberg, S., Beckstrom-Sternberg, J., Barrett, M., Long, J., Chinnaiyan, A., et al. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res 21 (2011), 47–55.
32. Huang, S., Gulzar, Z.G., Salari, K., Lapointe, J., Brooks, J.D., Pollack, J.R., Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness. Oncogene 31 (2012), 4164–4170.
33. Sakamoto, I., Kishida, S., Fukui, A., Kishida, M., Yamamoto, H., Hino, S., Michiue, T., Takada, S., Asashima, M., Kikuchi, A., A novel beta-catenin-binding protein inhibits beta-catenin-dependent Tcf activation and axis formation. J Biol Chem 275 (2000), 32871–32878.